Dr. Paul Billings joins Trovagene's Scientific Advisory Board
SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Trovagene,
Inc. (NASDAQ: TROV), a developer of transrenal molecular
diagnostics, announced today that Dr. Paul
Billings has joined the Company's Scientific Advisory Board.
A board certified internist and clinical geneticist, Dr.
Paul R. Billings currently serves as
Chief Medical Officer at Life Technologies Corporation. Dr.
Billings brings extensive expertise and clinical experience in the
areas of genomics and molecular medicine.
(Logo:
http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)
"We are honored that Dr. Billings will be collaborating with
Trovagene," states Antonius Schuh, Ph.D., chief executive officer
of Trovagene. "He specializes in improving patient care through
expanding the use of medically relevant genomic technologies in
clinical settings," he continues, "and his expertise is critical he
helps shape policy in the rapidly evolving field of genomic
medicine."
Dr. Billings has had a distinguished career as a physician,
business executive and researcher. He has authored nearly 200
publications and books on genomic medicine and currently serves on
the Scientific Advisory Board of the Food and Drug Administration,
the Genomic Medicine Advisory Committee at the Department of
Veterans Affairs, and the National Academy of Sciences Institute of
Medicine's Roundtable on Genomics. Most recently, he served as
Director and Chief Scientific Officer of the Genomic Medicine
Institute at El Camino Hospital, the largest community hospital in
the Silicon Valley. Previously, he was senior vice president for
corporate development at Laboratory Corporation of America Holdings
(LabCorp). He has been a founder or chief executive officer of
companies involved in genetic and diagnostic medicine, including
GeneSage Inc., Omicia, Inc. and CELLective Dx Corporation. Dr.
Billings has held academic appointments at Harvard Medical School, Stanford School of Medicine
and the University of California,
Berkeley, and has served as a physician at a number of
medical centers throughout the country, including the University of California, San Francisco. Dr.
Billings holds an M.D. from Harvard Medical
School and a Ph.D. in immunology, also from Harvard University.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is developing its patented technology
for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that
cross the kidney barrier and can be detected in urine.
Trovagene is leveraging its intellectual property in oncogene
mutations via out-licensing and use of its transrenal technologies
to extend oncogene mutation detection using urine as a
sample. As a non-invasive and abundant sample, urine may
overcome many of the cost and collection challenges associated with
biopsy, as well as the volume limitations of blood.
Trovagene has a strong patent position as it relates to
transrenal molecular testing. It has U.S. and European patent
applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and
genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid
leukemia (AML) and mutations in the SF3B1 gene, which have been
shown to be associated with chemotherapy response in chronic
lymphocytic leukemia (CLL) patients.
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on Trovagene's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our ability to continue as
a going concern; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties of government or
third party payer reimbursement; limited sales and marketing
efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. As with any medical diagnostic tests under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this
press release will be completed or successful or that any product
will receive regulatory approval for any indication or prove to be
commercially successful. Trovagene does not undertake an obligation
to update or revise any forward-looking statement. Investors
should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and
other periodic reports filed with the Securities and Exchange
Commission.
Contact
Trovagene,
Inc.
Charlie
Rodi
Vice
President and Chief Scientific Officer
+1 (858)
952-7670
crodi@trovagene.com
www.trovagene.com
SOURCE Trovagene, Inc.